Correction to: Lane et al., Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.

Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. J Med Econ 2017;21:144-151. https://doi.org/10.1080/13696998.2017.1384383

When the above article was first published, Table 4 contained errors in the column headings. A corrected version of the table is provided below.

Table 4 Breakdown of treatment costs in the reference case analysis

	Type 1 basal-bolus			Type 2 basal-only
	Insulin glargine cost (USD)	Insulin degludec cost (USD)	Difference (USD)	Insulin glargine cost (USD)	Insulin degludec cost (USD)	Difference (USD)
Basal insulin cost (USD)	3705.46	4254.21	+548.75	7547.89	8576.34	+1028.45
Bolus insulin cost (USD)	3382.11	3382.11	0.00	0.00	0.00	0.00
Non-severe daytime hypoglycemia cost (USD)	188.99	188.99	0.00	19.73	15.75	−3.98
Non-severe nocturnal hypoglycemia cost (USD)	37.96	28.77	−9.19	9.49	7.20	−2.30
Severe hypoglycemia cost (USD)	885.17	657.74	−227.44	225.09	110.41	−114.68
Total cost (USD)	8199.69	8511.81	+312.12	7802.20	8709.69	+907.49

The authors apologize for these errors.